

AMENDED CLAIM SET

1. (Original) Pharmaceutical composition characterized by containing Silymarin and Carbopol and a pharmaceutically acceptable vehicle.

2. (Original) Composition in accordance with claim 1 characterized by containing 3 to 7% Silymarin and 0.2 to 0.6% Carbopol.

3. (Original) Composition in accordance with claim 2 where it preferably contains 5% Silymarin and 0.5% Carbopol.

4. (Original) Composition in accordance with claims 1 to 3 where the pharmaceutical composition may be in the form of an oral dose.

5. (Original) Composition in accordance with claim 4 where the oral form may be a suspension, oral solution, emulsion, gel, hard gelatin capsule, soft gelatin capsule, immediate release tablet, controlled release tablet, prolonged release or sustained release tablet.

6. (Original) Composition in accordance with claim 5 where it is preferably in the form of an oral suspension.

7. Cancelled.

8. Cancelled.

9. Cancelled.

10. (Original) Procedure for obtaining the composition of claims 1 to 3 consisting of the following steps:

- a) Dissolution of 0.2 to 0.6% of Carbopol in deionized water, subjecting it to agitation for a period of time of 50 to 90 minutes.
- b) Addition of Silymarin in a percentage of 3 to 7 to the foregoing dissolution and subjected to agitation for a minimum period of one hour until a homogenous mixture is obtained.

11. (Original) Procedure in accordance with claim 9 where preferably 0.5% of Carbopol and 5% of Silymarin are dissolved.

12. (Original) Process in accordance with claim 9 where it optionally has a subsequent step of solubilization.

13. (Original) Process in accordance with claim 9 where it optionally has a subsequent step of emulsification.

14. (Original) Process in accordance with claim 9 where it optionally has a subsequent step of gelation.

15. (Original) Process in accordance with claim 9 where it optionally has a subsequent step of encapsulation.

16. (Original) Process in accordance with claim 9 where it optionally has a subsequent tablet-making step.

17. Cancelled.

18. Cancelled.

19. (New) The use of the composition with Silymarin and Carbopol for the manufacture of a medicine that is useful in the regeneration of the damaged pancreatic cells, for the recovery of the endocrine pancreatic function.

20. (New) The use in accordance with claim 19, wherein said composition contains 3 to 7% Silymarin and 0.2 to 0.6% Carbopol.

21. (New) The use in accordance with claim 19, wherein said composition contains 5% Silymarin and 0.5% Carbopol.

22. (New) The use in accordance with claim 19, where the composition is administered in the form of an oral dose.

23. (New) The use in accordance with claim 22, wherein the oral dose may be a suspension, oral solution, emulsion, gel, hard gelatin capsule, soft gelatin capsule, immediate release tablet, controlled release tablet, prolonged release or sustained release tablet.

24. (New) The use in accordance with claim 23, wherein the oral dose is in the form of an oral suspension.

25. (New) The use in accordance with claim 19, wherein the functioning of the  $\beta$ -pancreatic cells causes the production of insulin.

26. (New) The use in accordance of claim 25, for the treatment of diabetes mellitus.